logo
Ambulance service calls women ‘people with breasts'

Ambulance service calls women ‘people with breasts'

Yahoo11-03-2025

St John Ambulance has been accused of 'erasing women' after issuing guidance on how to perform CPR on 'people with breasts'.
Its web page stated it aimed to address the fact that 'people with breasts are statistically less likely to receive bystander CPR than men'.
However, gender critical campaigners said a failure to use the word 'women' in the guide was 'an unfortunate example of misogyny' in 'a life or death situation'.
The first aid charity is the latest organisation to come under fire for using 'gender neutral language' in an effort to be more inclusive of transgender people.
The guide, which also explains how to use a defibrillator, also advises readers they should 'remove bras or binding' if the casualty is wearing one, in order to reach their bare chest.
'Binders' are a form of underwear usually worn by transgender men in order to temporarily flatten breasts and create a more masculine appearance.
Attention to the web page was drawn by campaign group Women's Rights Network (WRN) – which posted a screenshot of its title on X.
'Immediate medical treatment is required for @stjohnambulance,' the post read.
'They've developed chronic amnesia and forgotten the word for half the population.
'Those 'people with breasts' are women. They have no problem with saying 'men' so why don't we merit the same respect?'
The post provoked a series of angry responses, including from those who described the guide as 'insulting', with some pointing out the 'double standards' of referring to 'men' in the same headline.
Cathay Larkman, one of WRN's directors, told The Telegraph: 'From our point of view, this is just another example of misogyny.
'If St John Ambulance are referring to women, then they need to say 'women'.
'Clear message is extremely important when it comes to health and in the case of CPR, it's potentially a life or death situation.'
Ms Larkman added: 'It's another incident of erasing women.'
Some commenting on the X post pointed out that St John Ambulance had run a campaign which aimed to tackle gender disparity in CPR.
In a separate web page, it cited research that showed 'a third of Brits are afraid to give CPR to a woman because they are worried about touching breasts'.
The text then continued to refer to 'women' throughout.
Maya Forstater, chief executive of charity Sex Matters, said: 'It beggars belief that some of the worst offenders when it comes to butchering factual, sex-based language are medical organisations.'
She added: 'Like many organisations, St John Ambulance never used to have a problem calling women what they are until activists began to insist that this was offensive. To claw back credibility, St John Ambulance should revoke this guidance and reissue it using factual and commonly understood language.'
A St John Ambulance spokesperson said: 'According to research women are less likely than men to receive lifesaving CPR in public because people are afraid to touch breasts. For International Women's Day this week we revisited our CPR Bra campaign that focused on saving more women's lives to remind people of the first aid steps to improve the women's chances of survival.
'This reluctance to give CPR affects every 'body' with breasts and the CPR guidance on our web pages seeks to convey this important message. We have reviewed the title of the CPR guidance on our website and are improving the wording to ensure it reflects everybody St John seeks to help.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Brits issued Covid booster warning as cases of new strain rise
Brits issued Covid booster warning as cases of new strain rise

Yahoo

time3 days ago

  • Yahoo

Brits issued Covid booster warning as cases of new strain rise

Brits have been urged to get their Covid booster jabs, as experts warned of a rise in cases following a recent spell of warm weather. The message comes after health experts also warned of a new COVID-19 variant, with cases of the strain are on the rise around the world. Covid NB.1.8.1 is a variation of the XDV.1.5.1 strain and was first detected back in January 2025. Ifti Khan, superintendent pharmacist at Well Pharmacy, urged those eligible to book as soon as possible and get the booster while it is still available. He said: 'Covid will most likely rise coming into the end of spring and into summer as people mix with friends and family more often. 'We know from previous boosters that they are effective in making sure that patients' symptoms are not as severe as they might have been without so I would urge patients to pop into their local Well Pharmacy store and get their jab. 'Patients have just over two weeks as the spring booster programme ends on June 17 so it would be my hope that those who can get a jab, opt to do so before enjoying socialising during summer.' Mr Khan warned that at this time of year, some people may believe they have hay fever as early symptoms of Covid include a runny or blocked nose or a sore throat. Covid tests can be obtained at any Well Pharmacy. The WHO has placed the Covid NB.1.8.1 "under monitoring" due to the rise in cases worldwide. It is one of six COVID-19 variants currently being monitored. The new 'Strategic and operational plan for coronavirus disease threat management: at a glance' sets out the global framework for supporting Member States in the sustained, integrated, evidence-based management of coronavirus disease threats, including #COVID19, MERS, and… — World Health Organization (WHO) (@WHO) May 28, 2025 However, the WHO stated that the risk posed by the new variant was "low," and that approved COVID-19 vaccines are expected to be effective against it. The world health experts, in a recent risk evaluation, said: "Despite a concurrent increase in cases and hospitalisations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation. The WHO added: "The available evidence on NB.1.8.1 does not suggest additional public health risks relative to the other currently circulating Omicron descendent lineages." COVID NB.1.8.1 has already been detected in 22 countries. These include the likes of Australia, China, Hong Kong, Thailand and the US, according to The Independent. The coming COVID-19 Winter Surge in Australia will show the world where we are actually headed is happening in South-Eats Asia and East Asia are just the 'preludes'...watch how NB.1.8.1 spawns are evolving including PQ.1, PQ.2 and even sub-lineages like PE.1. — Thailand Medical News (@ThailandMedicaX) June 4, 2025 Cases of the NB.1.8.1 variant have also been confirmed in Northern Ireland, Wales, and "popular British tourist hotspots", the news outlet added.

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

Yahoo

time3 days ago

  • Yahoo

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

Bayer subsidiary Vividion Therapeutics has secured exclusive worldwide rights to develop and commercialise VVD-214, the Werner helicase (WRN) covalent inhibitor, enhancing its oncology pipeline. Roche and Vividion discovered and developed VVD-214 through a global partnership and licence agreement. In 2020, the companies agreed to discover and develop small molecules for a range of therapeutic targets. The acquisition of VVD-214 rights by Vividion complements its portfolio of investigational therapeutics aimed at treating cancers and immune disorders. Preliminary data from a Phase I trial indicated that the therapy is well-tolerated and exhibits signs of activity. The trial is assessing VVD-214 as a single agent and in conjunction with pembrolizumab for those with various solid tumours showing microsatellite instability (MSI), such as endometrial, colorectal, gastric and ovarian cancers. WRN is a deoxyribonucleic acid (DNA) repair enzyme and a synthetic lethal target for cancers with MSI. VVD-214's mechanism aims to induce lethal DNA damage in these cancers while sparing healthy cells. This approach could offer a new treatment avenue for patients with limited options, particularly those who relapse or become refractory to immune checkpoint inhibitors. Vividion Therapeutics CEO Aleksandra Rizo stated: 'Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion. 'We are eager to progress development of this compound, building on the encouraging clinical data we've seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.' Vividion has Phase I trials for other potential oral cancer therapies, including a Kelch-like ECH-associated protein 1 (KEAP1) activator, a RAS-phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and a signal transducer and activator of transcription 3 (STAT3) inhibitor. The company is progressing the discovery of several drug programmes towards the clinic and has a pipeline of early discovery opportunities in immunology and oncology, utilising its chemoproteomics platform. "Bayer subsidiary Vividion secures rights to Werner helicase inhibitor" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

Yahoo

time4 days ago

  • Yahoo

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

Bayer subsidiary Vividion Therapeutics has secured exclusive worldwide rights to develop and commercialise VVD-214, the Werner helicase (WRN) covalent inhibitor, enhancing its oncology pipeline. Roche and Vividion discovered and developed VVD-214 through a global partnership and licence agreement. In 2020, the companies agreed to discover and develop small molecules for a range of therapeutic targets. The acquisition of VVD-214 rights by Vividion complements its portfolio of investigational therapeutics aimed at treating cancers and immune disorders. Preliminary data from a Phase I trial indicated that the therapy is well-tolerated and exhibits signs of activity. The trial is assessing VVD-214 as a single agent and in conjunction with pembrolizumab for those with various solid tumours showing microsatellite instability (MSI), such as endometrial, colorectal, gastric and ovarian cancers. WRN is a deoxyribonucleic acid (DNA) repair enzyme and a synthetic lethal target for cancers with MSI. VVD-214's mechanism aims to induce lethal DNA damage in these cancers while sparing healthy cells. This approach could offer a new treatment avenue for patients with limited options, particularly those who relapse or become refractory to immune checkpoint inhibitors. Vividion Therapeutics CEO Aleksandra Rizo stated: 'Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion. 'We are eager to progress development of this compound, building on the encouraging clinical data we've seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.' Vividion has Phase I trials for other potential oral cancer therapies, including a Kelch-like ECH-associated protein 1 (KEAP1) activator, a RAS-phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and a signal transducer and activator of transcription 3 (STAT3) inhibitor. The company is progressing the discovery of several drug programmes towards the clinic and has a pipeline of early discovery opportunities in immunology and oncology, utilising its chemoproteomics platform. "Bayer subsidiary Vividion secures rights to Werner helicase inhibitor" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store